

2014

Table of Contents

Follow this and additional works at: <https://scholarship.law.marquette.edu/iplr>



Part of the [Law Commons](#)

Repository Citation

Table of Contents, 18 Marq. Intellectual Property L. Rev. (2014).

Available at: <https://scholarship.law.marquette.edu/iplr/vol18/iss1/9>

This Prefatory Matter is brought to you for free and open access by the Journals at Marquette Law Scholarly Commons. It has been accepted for inclusion in Marquette Intellectual Property Law Review by an authorized editor of Marquette Law Scholarly Commons. For more information, please contact elana.olson@marquette.edu.

**MARQUETTE INTELLECTUAL PROPERTY
LAW REVIEW**

Volume 18

Winter 2014

Number 1

2013 ANNUAL HELEN WILSON NIES LECTURE

DIAGNOSTIC PATENTS AT THE SUPREME COURT

Arti K. Rai..... 1

**INTELLECTUAL PROPERTY POLICY FORUM:
PHARMACEUTICAL DEVELOPMENT AND HEALTHCARE
INNOVATION**

FOREWORD FROM THE EDITORS 13

TOMMY THOMPSON, *Drug Development – Translating Basic Research into
New Medicines* 15

G. STEVEN BURRILL, *Forward-looking View of Healthcare Innovation, from
a Leading Life Science Venture Capitalist* 17

DAVID MEININGER, *The Increasing Importance of Biologics-based Drugs in
Pharmaceutical Pipelines* 19

GARRET A. FITZGERALD, *Need for New IP Approaches to Facilitate
Collaborative (Academic-Industrial) Drug Development*..... 21

BRUCE BLOOM, *New Business Models to Find Cures and Lower Healthcare
Costs: A Role for Drug Repurposing* 23

RAMAIAH MUTHYALA, *Repurposing & Collaborative Drug Development for
Rare Diseases* 25

HARSHA K. RAJASIMHA, *The Future of Clinical Trials: More Transparency
and Pharmacogenomics* 27

JOHN R. RAYMOND, *Implications of Genomics Advances for Drug Discovery,
Clinical Therapies, & Rare Disease Research*..... 29

HUGH LAVERTY & MAGALI POINOT, *Intellectual Property Rights (IPR) in
Collaborative Drug Development in the EU: Helping a European
Public-Private Partnership Deliver – the Need for a Flexible Approach
to IPR* 31

INTELLECTUAL PROPERTY POLICY FORUM ARTICLES

A NEW FRAMEWORK FOR ASSESSING CLINICAL DATA TRANSPARENCY
INITIATIVES

Erika Lietzan..... 33

ANCILLARY ORDERS OF COMPULSORY LICENSING AND THEIR
COMPATIBILITY WITH THE TRIPS AGREEMENT

Richard Li-dar Wang 87

INTELLECTUAL PROPERTY POLICY FORUM COMMENTS

THE NEW ERA OF BIOLOGIC REGULATION AND PATENTING UNDER THE
AMERICA INVENTS ACT
David I. Rucker 107

REPURPOSING – FINDING NEW USES FOR OLD (AND PATENTED) DRUGS:
BRIDGING THE “VALLEY OF DEATH,” TO TRANSLATE ACADEMIC
RESEARCH INTO NEW MEDICINES
Daniel S. Sem..... 139

**INTERNATIONAL INTELLECTUAL PROPERTY SCHOLARS
SERIES**

TRADEMARKS UNDER THE NORTH AMERICAN FREE TRADE AGREEMENT
(NAFTA), WITH REFERENCES TO THE CURRENT MEXICAN LAW
Roberto Rosas 167

ARTICLES

TERRITORIALITY CHALLENGES IN PROTECTING TRADEMARK INTERESTS
IN THE SYSTEM OF GENERIC TOP-LEVEL DOMAINS (GTLDS)
Jesse Kim 217

COMMENTS

HOW MEDIA GOT THE BIGGEST BITE OF (THE) APPLE: A LOOK AT THE
MEDIA MISPERCEPTION IN THE APPLE-SAMSUNG CASE
Neha Pathak..... 237